应用β受体阻滞剂治疗哈萨克族及汉族高血压患者的疗效观察
摘要
目的:本研究旨在评价β受体阻滞剂酒石酸美托洛尔片治疗哈萨克族及汉族高血压患者的疗效,不同民族的高血压患者对某一种药物在降压治疗的疗效上可能有一定的差异。方法:选择在新疆医科大学第一附属医院住院的患有原发性高血压病的患者共106例,其中汉族56例,哈萨克族50例。入院后监测患者血压,治疗上给予β受体阻滞剂酒石酸美托洛尔片降压治疗。治疗期间检测患者血压,分析汉族和哈萨克族血压变化情况。数据采用SPSS13.0数据包处理。结果:t检验分析结果显示:哈萨克族及汉族两组患者在用药前血压相比无统计学意义,P>0.05。用药后两组患者收缩压systemic blood pressure(SBP),舒张压diastolic blood pressure(DBP)较用药前明显下降,有统计学意义,P<0.05。两组治疗疗效之间比较无统计学意义,P>0.05。结论:在本研究中,我们比较了β受体阻滞剂酒石酸美托洛尔片在治疗哈萨克族及汉族高血压患者的疗效。治疗后两组血压均有明显下降,哈萨克族及汉族两个民族高血压患者治疗疗效之间无明显差异。
Objective:The aim of the research is to evaluate the curative of metoprolol for the patients with primary hypertension in Han people and Kazak. It will have different curative effect with the same drugs. Methods:106 patients with primary hypertension were selected in The first hospital of Xinjiang Medical University. There are 56 patients are Han people, 50 patients are Kazak. They come to the hospital, then monitor the hypertension, take the metoprolol to them, and monitor the blood pressure, and analyzed the different between the two groups. Then the dada were analyzed by the SPSS13.0 software, P<0.05was looked as statistical significance. Results:There was no statistical significance between Han people and Kazak before they take the drugs(P>0.05).In group Han people, after drugs systemic blood pressure (SBP)and diastolic blood pressure (DBP)descended significantly than that before they take the drugs (P<0.05). In group Kazak, after drugs SBP and DBP descended significantly than that before they take the drugs (P<0.05).After drugs both two groups SBP and DSP was no statistical significance (P>0.05). Conclusions:We take the curative of metoprolol for the patients with primary hypertension in Han people and Kazak in this research. The SBP and DBP was significantly lower after drugs with both two groups, but there was no statistical significance between the curative of the two groups.
Objective:The aim of the research is to evaluate the curative of metoprolol for the patients with primary hypertension in Han people and Kazak. It will have different curative effect with the same drugs. Methods:106 patients with primary hypertension were selected in The first hospital of Xinjiang Medical University. There are 56 patients are Han people, 50 patients are Kazak. They come to the hospital, then monitor the hypertension, take the metoprolol to them, and monitor the blood pressure, and analyzed the different between the two groups. Then the dada were analyzed by the SPSS13.0 software, P<0.05was looked as statistical significance. Results:There was no statistical significance between Han people and Kazak before they take the drugs(P>0.05).In group Han people, after drugs systemic blood pressure (SBP)and diastolic blood pressure (DBP)descended significantly than that before they take the drugs (P<0.05). In group Kazak, after drugs SBP and DBP descended significantly than that before they take the drugs (P<0.05).After drugs both two groups SBP and DSP was no statistical significance (P>0.05). Conclusions:We take the curative of metoprolol for the patients with primary hypertension in Han people and Kazak in this research. The SBP and DBP was significantly lower after drugs with both two groups, but there was no statistical significance between the curative of the two groups.
引文
[1]赵水平.心脏内科研修精要[M].长沙:湖南科学技术出版社, 2002.115.
[2]高血压防治指南修订委员会.中国高血压防治指南. 2005年修订版.
[3] Vasna RS, Beiser A, Seshadri S, et al,Residual lifetime risk for developing hypertension in middle-aged women nad men:The Framingham Heart study[J].JAMA.2002,287:1003-1010.
[4] Dzida G et al.Polymorphisms of anagiotensin-converting enzyme and angiotensin 11 receptor type 1 genes in essential hypertension in a Polish population[J]. J Med Sci Monit.2001, 7(6): 1236-1241.
[5] Mein CA. Caulfield. Dobson RJ. Et al. Genetic of essential Hypertension[J].Human Molecular Genetics. 2004, 13: R169-75.
[6]徐新娟,汪师贞.新疆地区高血压流行病学调查研究回顾[J].新疆医科大学学报.2004, 27(3):312-314.
[7]夏晓利,别革兰,路航,等.新疆哈萨克族、汉族高血压点差分析[J].高血压杂志.2000, 8(4):283-284.
[8]张明涛,陈平虎.汉、哈两民族农民中高血压患病情况及血压值比较分析[J].中华流行病学杂志.1984, 5(l):29-34.
[9]李南方,周玲,曹梅,等.新疆和丰县牧区高血压病流行病学调查报告[J].现代预防医学. 2003, 30(2): 141-143.
[10] Bryan Williams.β-blockers and the treatment of hypertension. Journal of Hypertension, 2007, 25: 1251-1253.
[11] Rossi G,Rossi A, SlrfedoS, et al.Hypertensive cerebrovas-cular disease and the rennin-angiotensin system [J]. Stroke, 1995; 20: 1700-1706.
[12]石静萍,张颖冬,葛剑青等.急性脑梗死患者血浆肾素、血管紧张素Ⅱ的变化及临床意义[J].临床神经病学子杂志, 2002, 15: 204-206.
[13] KHAN N, MCALISTER FA. Re-examining the efficacy ofβ-blockers for the treatment of hypertension: a meta-analysis[J]. CMAJ, 2006, 174: 1736-1742.
[14]余振球,孔羽.β受体阻滞剂在治疗高血压中的地位[J].中国处方药, 2006, 1(46): 14-17.
[15] Chobanha AV,Bakris GL,Black HR, et al. The senventh report of the Joint National Comnuttee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report JAMA,2003,289:2560-2572.
[16] European Society of Hypertension-European Society of Cardiology Cuidelines Committee.2003 European Society of Hypentension-European Society of Cardiology guidelines for the management of arterial of arterial hypertension. J Hypertens, 2003, 21:1011-1053 .
[17] Broum MJ et al.BMJ, 1997; 314(7089): 1258～1261.
[18]吴先萍,王大中,沈力平,等.高血压的遗传流行病学研究[J].中华流行病学杂志, 1992, 13(6): 355～357.
[19]心血管病及其危险因素对比研究协作组. 9组人群血压及体重流行病学的对比研究[J].北京医学,1987,9(1):41～44.
[20] Stamler R,Smith CA,Fleiss JL,et al. Family (parental) history and prevalence of hypertension[J].JAMA,1979:241～248.
[21] Campbell D J.Tissue renin-angiotension system:sites of angiotension formation.J Car-diovasdc Pharmacol, 1987, 10(Suppl 7): S1-S8 .
[22]夏钦贵.局部肾素血管紧张素系统对心血管功能的调节作用.生理科学进展, 1994, 25(1):95.
[23]朱文玲.β受体阻滞剂在冠心病中的应用.北京医学[J], 2005, 7(5):293-294.
[24]陈洁,张水旺,刘卓敏等.美托洛尔治疗慢性心力衰竭早期与长期疗效观察[J].中西医结合心脑血管病杂志, 2005, 3(2):111-113.
[25]曹仁颐.高血压病治疗进展[J].医师进修杂志, 1986,9(7):16-18
[26]王静,刘力生.高血压的阶梯治疗[J].中级医刊, 1986, 21(12): 17-21.
[27]汪为平.警惕药物性高血压[J].医师进修杂志, 1986, 9(7): 9-11.
[28] Muntzel M, Drueke T.A comprehensive review of the salt and blood pressure relationship.Am J Hypertens, 1992, 5:1S.
[29] Weinberger M,Salt sensitivity of blood pressure in humans.Hypertension,1996,27(part 2):481.
[30]何虹,汪涛,减益民.盐敏感性高血压的相关因素[J].心脏杂志2004, 16(1): 83一85.
[31]李玉明,盐敏感性高血压:历史、现状、展望[J].中华心血管病杂志. 2003, 31(12): 955-957.
[32] De Wardener HE, MacGregor GA.Sodium and blood pressure[J]. Curt Opin Cardiol. 2002, 17: 360-367.
[33]孙海励,郭丹军,关炳江等.高血压患者胰岛素受体基因突变对相关激素的影响〔J〕.中华心血管杂志, 1997, 25(6): 419.
[34]庞莉,孙海励,郭丹军等.原发性高血压家系胰岛素受体基因第17外显子变异分析〔J〕.中国医学科学院学报, 1997, 19(2):83.
[35]张耿新.从佛山看广东富裕地区高血压病流行趋势.岭南心血管杂志, 1998, 9(4): 55,
[36]刘力生.预防发展中国家的心血管病大流行.中华心血管病杂志, 2001, 29(7):385.
[37] Kokkinos P, Chrysohoou C, Panagiotakos D, et al. Beta-block-ade mitigates exercise blood pressure in hypertensive male patients[J].J Am Coll Cardiol,2006,47:794-798
[38]于波.β受体阻滞剂治疗高血压的回顾与展望.临床药物治疗杂志[J], 2007: 5 (5): 32-35.
[39]陈洁,张水旺,刘卓敏等.美托洛尔治疗慢性心力衰竭早期与长期疗效观察[J]。中西医结合心脑血管病杂志, 2005, 3(2): 111-113.
[40]胡大一,吴彦.β受体阻滞剂治疗高血压过时了吗?—评英国高血压指南[J].中华内科杂志, 2006 :45(12): 971-972.
[41]全国血压抽样调查协作组:中国人群高血压患病率及其变化趋势[J].高血压杂志,1995,(3)增刊:23.
[42]王坤,郭艳英,敖由特,等.论新疆博尔塔拉蒙古自治州蒙、哈、维、汉4民族30岁以上高血压及部分有关危险因素调查[J].高血压杂志,2006,14(3):214-216.
[43] KHAN N, MCALISTER FA. Re-examining the efficacy ofβ-blockers for the treatment of hypertension:a meta-analysis[J].CMAJ, 2006, 174: 1736-1742.
[44]余振球,孔羽.β受体阻滞剂在治疗高血压中的地位[J].中国处方药, 2006, 1(46): 14-17.
[45] Psaty BM,Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive. Hypertension, 2005, 46: 205-209.
[46]刘弢, ,谢英, ,周玉杰等.琥珀酸美托洛尔缓释片治疗轻中度原发性高血压的临床研究[J].中国心血管杂志,2007: 12(4):287-289.
[47]施仲伟. 2007年欧洲高血压指南新动向[J].心血管网特刊, 2007年9月10日第8版.
[1]赵水平.心脏内科研修精要[M].长沙:湖南科学技术出版社, 2002.115.
[2]高血压防治指南修订委员会.中国高血压防治指南. 2005年修订版.
[3] .Bryan Williams.β-blockers and the treatment of hypertension. Journal of Hypertension, 2007, 25: 1251-1253.
[4]于波.β受体阻滞剂治疗高血压的回顾与展望.临床药物治疗杂志[J], 2007: 5 (15): 32-35.
[5] H T Ong.重新审视β受体阻滞剂在高血压及心血管疾病中的地位.中国处方药[J], 2007, 6(63):67-69
[6] MERIT-HF study group.Effect of metopralol CR/XL in chronic heart failure:Metoprolol CR/XL randomised intervention trial in congestive heart failure(MERIT-HF).Lancet, 1999, 353: 2001-2007.
[7]霍震.β受体阻滞剂在慢性心衰中的应用.现代临床医学[J], 2007: 33suppl(1):19-21.
[8]马红,刘志军.β受体阻滞剂在治疗高血压病中的地位.中华心血管病杂志, [J], 2006: 34(7): 660-661.
[9]程远植.正确使用β受体阻滞剂为高血压患者制定合理个体化方案[J].临床药物治疗杂志, 2007, 5(5): 27-28.
[10] KHAN N, MCALISTER FA. Re-examining the efficacy ofβ-blockers for the treatment of hypertension: a meta-analysis[J]. CMAJ, 2006, 174: 1736-1742.
[11]余振球,孔羽.β受体阻滞剂在治疗高血压中的地位[J].中国处方药, 2006, 1(46): 14-17.
[12]陈清华,铙邦复.β受体阻滞剂在降压治疗中的地位.现代医药卫生[J], 2007, 23(4): 475-476.
[13] Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardio, 1994, 74(7) :674-680.
[14]朱文玲.β受体阻滞剂在冠心病中的应用.北京医学[J], 2005, 7(5): 293-294.
[15]陈洁,张水旺,刘卓敏等.美托洛尔治疗慢性心力衰竭早期与长期疗效观察[J].中西医结合心脑血管病杂志, 2005, 3(2): 111-113.
[16]胡大一,吴彦.β受体阻滞剂治疗高血压过时了吗?—评英国高血压指南[J].中华内科杂志, 2006: 45(12): 971-972.
[17]刘弢,谢英,周玉杰等.琥珀酸美托洛尔缓释片治疗轻中度原发性高血压的临床研究[J].中国心血管杂志, 2007: 12 (4): 287-289.
[18]施仲伟. 2007年欧洲高血压指南新动向[J].心血管网特刊, 2007年9月10日第8版.
[19]孙宁玲.正确理解英国NICE指南定位β受体阻滞剂在高血压治疗中的作用[J].中华高血压杂志, 2007, 15 (1): 4-6.
[2]高血压防治指南修订委员会.中国高血压防治指南. 2005年修订版.
[3] Vasna RS, Beiser A, Seshadri S, et al,Residual lifetime risk for developing hypertension in middle-aged women nad men:The Framingham Heart study[J].JAMA.2002,287:1003-1010.
[4] Dzida G et al.Polymorphisms of anagiotensin-converting enzyme and angiotensin 11 receptor type 1 genes in essential hypertension in a Polish population[J]. J Med Sci Monit.2001, 7(6): 1236-1241.
[5] Mein CA. Caulfield. Dobson RJ. Et al. Genetic of essential Hypertension[J].Human Molecular Genetics. 2004, 13: R169-75.
[6]徐新娟,汪师贞.新疆地区高血压流行病学调查研究回顾[J].新疆医科大学学报.2004, 27(3):312-314.
[7]夏晓利,别革兰,路航,等.新疆哈萨克族、汉族高血压点差分析[J].高血压杂志.2000, 8(4):283-284.
[8]张明涛,陈平虎.汉、哈两民族农民中高血压患病情况及血压值比较分析[J].中华流行病学杂志.1984, 5(l):29-34.
[9]李南方,周玲,曹梅,等.新疆和丰县牧区高血压病流行病学调查报告[J].现代预防医学. 2003, 30(2): 141-143.
[10] Bryan Williams.β-blockers and the treatment of hypertension. Journal of Hypertension, 2007, 25: 1251-1253.
[11] Rossi G,Rossi A, SlrfedoS, et al.Hypertensive cerebrovas-cular disease and the rennin-angiotensin system [J]. Stroke, 1995; 20: 1700-1706.
[12]石静萍,张颖冬,葛剑青等.急性脑梗死患者血浆肾素、血管紧张素Ⅱ的变化及临床意义[J].临床神经病学子杂志, 2002, 15: 204-206.
[13] KHAN N, MCALISTER FA. Re-examining the efficacy ofβ-blockers for the treatment of hypertension: a meta-analysis[J]. CMAJ, 2006, 174: 1736-1742.
[14]余振球,孔羽.β受体阻滞剂在治疗高血压中的地位[J].中国处方药, 2006, 1(46): 14-17.
[15] Chobanha AV,Bakris GL,Black HR, et al. The senventh report of the Joint National Comnuttee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report JAMA,2003,289:2560-2572.
[16] European Society of Hypertension-European Society of Cardiology Cuidelines Committee.2003 European Society of Hypentension-European Society of Cardiology guidelines for the management of arterial of arterial hypertension. J Hypertens, 2003, 21:1011-1053 .
[17] Broum MJ et al.BMJ, 1997; 314(7089): 1258～1261.
[18]吴先萍,王大中,沈力平,等.高血压的遗传流行病学研究[J].中华流行病学杂志, 1992, 13(6): 355～357.
[19]心血管病及其危险因素对比研究协作组. 9组人群血压及体重流行病学的对比研究[J].北京医学,1987,9(1):41～44.
[20] Stamler R,Smith CA,Fleiss JL,et al. Family (parental) history and prevalence of hypertension[J].JAMA,1979:241～248.
[21] Campbell D J.Tissue renin-angiotension system:sites of angiotension formation.J Car-diovasdc Pharmacol, 1987, 10(Suppl 7): S1-S8 .
[22]夏钦贵.局部肾素血管紧张素系统对心血管功能的调节作用.生理科学进展, 1994, 25(1):95.
[23]朱文玲.β受体阻滞剂在冠心病中的应用.北京医学[J], 2005, 7(5):293-294.
[24]陈洁,张水旺,刘卓敏等.美托洛尔治疗慢性心力衰竭早期与长期疗效观察[J].中西医结合心脑血管病杂志, 2005, 3(2):111-113.
[25]曹仁颐.高血压病治疗进展[J].医师进修杂志, 1986,9(7):16-18
[26]王静,刘力生.高血压的阶梯治疗[J].中级医刊, 1986, 21(12): 17-21.
[27]汪为平.警惕药物性高血压[J].医师进修杂志, 1986, 9(7): 9-11.
[28] Muntzel M, Drueke T.A comprehensive review of the salt and blood pressure relationship.Am J Hypertens, 1992, 5:1S.
[29] Weinberger M,Salt sensitivity of blood pressure in humans.Hypertension,1996,27(part 2):481.
[30]何虹,汪涛,减益民.盐敏感性高血压的相关因素[J].心脏杂志2004, 16(1): 83一85.
[31]李玉明,盐敏感性高血压:历史、现状、展望[J].中华心血管病杂志. 2003, 31(12): 955-957.
[32] De Wardener HE, MacGregor GA.Sodium and blood pressure[J]. Curt Opin Cardiol. 2002, 17: 360-367.
[33]孙海励,郭丹军,关炳江等.高血压患者胰岛素受体基因突变对相关激素的影响〔J〕.中华心血管杂志, 1997, 25(6): 419.
[34]庞莉,孙海励,郭丹军等.原发性高血压家系胰岛素受体基因第17外显子变异分析〔J〕.中国医学科学院学报, 1997, 19(2):83.
[35]张耿新.从佛山看广东富裕地区高血压病流行趋势.岭南心血管杂志, 1998, 9(4): 55,
[36]刘力生.预防发展中国家的心血管病大流行.中华心血管病杂志, 2001, 29(7):385.
[37] Kokkinos P, Chrysohoou C, Panagiotakos D, et al. Beta-block-ade mitigates exercise blood pressure in hypertensive male patients[J].J Am Coll Cardiol,2006,47:794-798
[38]于波.β受体阻滞剂治疗高血压的回顾与展望.临床药物治疗杂志[J], 2007: 5 (5): 32-35.
[39]陈洁,张水旺,刘卓敏等.美托洛尔治疗慢性心力衰竭早期与长期疗效观察[J]。中西医结合心脑血管病杂志, 2005, 3(2): 111-113.
[40]胡大一,吴彦.β受体阻滞剂治疗高血压过时了吗?—评英国高血压指南[J].中华内科杂志, 2006 :45(12): 971-972.
[41]全国血压抽样调查协作组:中国人群高血压患病率及其变化趋势[J].高血压杂志,1995,(3)增刊:23.
[42]王坤,郭艳英,敖由特,等.论新疆博尔塔拉蒙古自治州蒙、哈、维、汉4民族30岁以上高血压及部分有关危险因素调查[J].高血压杂志,2006,14(3):214-216.
[43] KHAN N, MCALISTER FA. Re-examining the efficacy ofβ-blockers for the treatment of hypertension:a meta-analysis[J].CMAJ, 2006, 174: 1736-1742.
[44]余振球,孔羽.β受体阻滞剂在治疗高血压中的地位[J].中国处方药, 2006, 1(46): 14-17.
[45] Psaty BM,Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive. Hypertension, 2005, 46: 205-209.
[46]刘弢, ,谢英, ,周玉杰等.琥珀酸美托洛尔缓释片治疗轻中度原发性高血压的临床研究[J].中国心血管杂志,2007: 12(4):287-289.
[47]施仲伟. 2007年欧洲高血压指南新动向[J].心血管网特刊, 2007年9月10日第8版.
[1]赵水平.心脏内科研修精要[M].长沙:湖南科学技术出版社, 2002.115.
[2]高血压防治指南修订委员会.中国高血压防治指南. 2005年修订版.
[3] .Bryan Williams.β-blockers and the treatment of hypertension. Journal of Hypertension, 2007, 25: 1251-1253.
[4]于波.β受体阻滞剂治疗高血压的回顾与展望.临床药物治疗杂志[J], 2007: 5 (15): 32-35.
[5] H T Ong.重新审视β受体阻滞剂在高血压及心血管疾病中的地位.中国处方药[J], 2007, 6(63):67-69
[6] MERIT-HF study group.Effect of metopralol CR/XL in chronic heart failure:Metoprolol CR/XL randomised intervention trial in congestive heart failure(MERIT-HF).Lancet, 1999, 353: 2001-2007.
[7]霍震.β受体阻滞剂在慢性心衰中的应用.现代临床医学[J], 2007: 33suppl(1):19-21.
[8]马红,刘志军.β受体阻滞剂在治疗高血压病中的地位.中华心血管病杂志, [J], 2006: 34(7): 660-661.
[9]程远植.正确使用β受体阻滞剂为高血压患者制定合理个体化方案[J].临床药物治疗杂志, 2007, 5(5): 27-28.
[10] KHAN N, MCALISTER FA. Re-examining the efficacy ofβ-blockers for the treatment of hypertension: a meta-analysis[J]. CMAJ, 2006, 174: 1736-1742.
[11]余振球,孔羽.β受体阻滞剂在治疗高血压中的地位[J].中国处方药, 2006, 1(46): 14-17.
[12]陈清华,铙邦复.β受体阻滞剂在降压治疗中的地位.现代医药卫生[J], 2007, 23(4): 475-476.
[13] Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardio, 1994, 74(7) :674-680.
[14]朱文玲.β受体阻滞剂在冠心病中的应用.北京医学[J], 2005, 7(5): 293-294.
[15]陈洁,张水旺,刘卓敏等.美托洛尔治疗慢性心力衰竭早期与长期疗效观察[J].中西医结合心脑血管病杂志, 2005, 3(2): 111-113.
[16]胡大一,吴彦.β受体阻滞剂治疗高血压过时了吗?—评英国高血压指南[J].中华内科杂志, 2006: 45(12): 971-972.
[17]刘弢,谢英,周玉杰等.琥珀酸美托洛尔缓释片治疗轻中度原发性高血压的临床研究[J].中国心血管杂志, 2007: 12 (4): 287-289.
[18]施仲伟. 2007年欧洲高血压指南新动向[J].心血管网特刊, 2007年9月10日第8版.
[19]孙宁玲.正确理解英国NICE指南定位β受体阻滞剂在高血压治疗中的作用[J].中华高血压杂志, 2007, 15 (1): 4-6.